Kariya Pharmaceuticals ApS: Financial statements 2023
CVR: 39270684
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -10,223,064 and a net result of DKK -8,022,549 compared with DKK -14,005,570 the year before. Equity in the 2023 report amounted to DKK -6,388,472. The company had 1 employee in the financial year.
- Gross Profit
- DKK -10,223,064
- Profit/Loss
- DKK -8,022,549
- Equity
- DKK -6,388,472
- Total Assets
- DKK 2,051,354
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -10.2 mio. | -8 mio. | -6.4 mio. | 1 |
| 2022 | - | -13.8 mio. | -14 mio. | -26.7 mio. | 1 |
| 2021 | - | -2.7 mio. | -3.3 mio. | -12.7 mio. | 1 |
| 2020 | - | -1.5 mio. | -2.2 mio. | -9.5 mio. | 2 |
| 2019 | - | -6.3 mio. | -7.3 mio. | -7.3 mio. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Kariya Pharmaceuticals ApS has published its annual report for 2022. Gross profit came to DKK -13,798,220, and the net result was DKK -14,005,570.
As of May 3, 2023, John Connell has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Claus Elsborg Olesen has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Ian Rodney Laquian has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Mikael Søndergaard Thomsen has joined the board of directors of Kariya Pharmaceuticals ApS.
As of April 27, 2023, Christian Hölscher has joined the board of directors of Kariya Pharmaceuticals ApS.
About Kariya Pharmaceuticals ApS
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.